Mohammed Sikander
University of Texas at Austin
Clonogenic assayCancerCA19-9microRNAChemistryApoptosisIn vitroImmunologyOrmeloxifenePTENPancreatic tumorCervical cancerPancaMetastasisProstate cancerPancreatic cancerGemcitabineCucurbitacinCucurbitacin DCell cycleCancer researchTransfectionCell growthMedicineBiologyCancer cell
23Publications
7H-index
278Citations
Publications 23
Newest
#1Mohammed Sikander (University of Texas at Austin)H-Index: 7
#1Mohammed Sikander (University of Texas at Austin)
Last. Meena Jaggi (University of Texas at Austin)H-Index: 1
view all 9 authors...
COVID-19 is known as one of the deadliest pandemics of the century. The rapid spread of this deadly virus at incredible speed has stunned the planet and poses a challenge to global scientific and medical communities. Patients with COVID-19 are at an increased risk of co-morbidities associated with liver dysfunction and injury. Moreover, hepatotoxicity induced by antiviral therapy is gaining importance and is an area of great concern. Currently, alternatives therapies are being sought to mitigate...
1 CitationsSource
#1Mohammed Sikander (UTHSC: University of Tennessee Health Science Center)H-Index: 7
#2Shabnam Malik (UTHSC: University of Tennessee Health Science Center)H-Index: 8
Last. Subhash C. ChauhanH-Index: 49
view all 11 authors...
Pancreatic cancer (PanCa) is one of the leading causes of death from cancer in the United States. The current standard treatment for pancreatic cancer is gemcitabine, but its success is poor due to the emergence of drug resistance. Natural products have been widely investigated as potential candidates in cancer therapies, and cucurbitacin D (Cuc D) has shown excellent anticancer properties in various models. However, there is no report on the therapeutic effect of Cuc D in PanCa. In the present ...
7 CitationsSource
#1Andrew E. Massey (UT: University of Tennessee)H-Index: 5
#2Mohammed Sikander (UT: University of Tennessee)H-Index: 7
Last. Subhash C. Chauhan (UT: University of Tennessee)H-Index: 49
view all 13 authors...
Abstract Pancreatic cancer (PanCa) is a major cause of cancer-related death due to limited therapeutic options. As pancreatic tumors are highly desmoplastic, they prevent appropriate uptake of therapeutic payloads. Thus, our objective is to develop a next-generation nanoparticle system for treating PanCa. We generated a multi-layered Pluronic F127 and polyvinyl alcohol stabilized and poly-L-lysine coated paclitaxel loaded poly(lactic-co-glycolic acid) nanoparticle formulation (PPNPs). This formu...
5 CitationsSource
#1Mohammed SikanderH-Index: 7
#2Shabnam MalikH-Index: 8
Last. Meena Jaggi (UT: University of Tennessee)H-Index: 36
view all 13 authors...
Background: Cervical cancer (CxC) is a leading cause of mortality and morbidity among women worldwide. Current chemotherapeutic agents for CxC have shown systemic toxicity in CxC patients. Ormeloxifene (ORM) is a non-toxic and non-steroidal drug with well-defined pharmacokinetic and pharmacodynamic properties in humans. Studies have shown its anti-cancer potential in various pre-clinical mouse models. Here, we have synthesized and characterized a novel analogue of ormeloxifene, Bromo-ormeloxifen...
Source
#1Neeraj Chauhan (UTHSC: University of Tennessee Health Science Center)H-Index: 24
#1Neeraj Chauhan (UTHSC: University of Tennessee Health Science Center)H-Index: 1
Last. Subhash C. Chauhan (UTHSC: University of Tennessee Health Science Center)H-Index: 49
view all 7 authors...
Background: Cervical cancer (CxCa) is one of the most common death related cancers among women around the world and associated with poor 5-year survival rate. Therefore, there is an urgent need to develop newer treatment modalities. Ormeloxifene (ORM) is a non-steroidal, Selective Estrogen Receptor Modulator (SERM) that is used as an oral contraceptive in humans. Recent investigations suggest that ORM exhibits potent anti-cancer activity against various types of cancers. Nanoparticulates offer t...
Source
#1Mehdi Chaib (UTHSC: University of Tennessee Health Science Center)H-Index: 3
#2Bilal Bin Hafeez (UTHSC: University of Tennessee Health Science Center)H-Index: 29
Last. Subhash C. Chauhan (UTHSC: University of Tennessee Health Science Center)H-Index: 49
view all 13 authors...
Background : Pancreatic cancer (PanCa) is one of the most lethal malignancy with a very poor survival rate in patients due to inadequate treatment options. Accumulating evidences suggest that tumor associated macrophages (TAMs) and reduce infiltration of CD8+ T-cell population provide tumor suppressive environment leading to advanced growth and metastasis of PanCa. Thus, targeting TAMs and enhancing infiltration of CD8+ T - cells to the tumor site by non-toxic agents could be an effective therap...
Source
#1Mohammed Sikander (UT: University of Tennessee)H-Index: 7
#2Shabnam Malik (UT: University of Tennessee)H-Index: 8
Last. Subhash C. ChauhanH-Index: 49
view all 12 authors...
Prostate cancer (PrCa) metastasis is the major cause of mortality and morbidity among men. Metastatic PrCa cells are typically adopted for aberrant glucose metabolism. Thus, chemophores that reprogram altered glucose metabolic machinery in cancer cells can be useful agent for the repression of PrCa metastasis. Herein, we report that cucurbitacin D (Cuc D) effectively inhibits glucose uptake and lactate production in metastatic PrCa cells via modulating glucose metabolism. This metabolic shift by...
13 CitationsSource
#1Mohammed Sikander (UT: University of Tennessee)H-Index: 7
#2Shabnam Malik (UT: University of Tennessee)H-Index: 8
Last. Subhash C. Chauhan (UT: University of Tennessee)H-Index: 49
view all 7 authors...
Background: Docetaxel (DTX) is an FDA approved drug for the treatment of advanced prostate cancer (PrCa). However, chemo-resistance and toxicity limits its use in clinic. Accumulating evidence suggests that activation of cancer stem cells (CSCs) is one of the mechanisms leading to developing chemo-resistance Therefore, identification of new pharmacophores that can target CSCs may improve the therapeutic efficacy of docetaxel for the treatment of advanced PrCa. Cucurbitacin D is one of the potent...
Source
#1Sheema Khan (UT: University of Tennessee)H-Index: 4
#2Kyle Doxtater (UT: University of Tennessee)
Last. Meena Jaggi (UT: University of Tennessee)H-Index: 36
view all 10 authors...
Objective: Pancreatic cancer (PanCa) is the third leading cause of cancer-related deaths in the U.S. MUC13, mucin, is aberrantly expressed in PanCa and its overexpression leads to tumorigenic and metastatic behavior of cancer cells. Herein, we investigate the role of MUC13 in tumor microenvironment (TME) that favors PanCa progression/metastasis and drug resistance. Methods: MUC13 expressing (Panc-1) and knockdown PanCa cells (HPAF-II) and pancreatic stromal cells (PSCs), derived from freshly col...
Source
#1Bilal Bin Hafeez (UT: University of Tennessee)H-Index: 29
#2Aditya Ganju (UT: University of Tennessee)H-Index: 12
Last. Meena Jaggi (UT: University of Tennessee)H-Index: 36
view all 15 authors...
Ormeloxifene (ORM), is a clinically approved selective estrogen receptor modulator, which has also shown excellent anti-cancer activity, thus it can be an ideal repurposing pharmacophore. Herein, we report therapeutic effects of ORM on prostate cancer (PrCa) and elucidate a novel molecular mechanism of its anti-cancer activity. ORM treatment inhibited epithelial to mesenchymal transition (EMT) process as evident by repression of N-cadherin, Slug, Snail, and vimentin, MMPs (MMP2 and MMP3), β-cate...
24 CitationsSource